Outcome comparison of radical prostatectomy versus seed brachytherapy for clinically localized prostate cancer using two biochemical recurrence definitions.
Biochemical recurrence definition
Localized prostate cancer
Radical prostatectomy
Seed brachytherapy
Journal
BMC surgery
ISSN: 1471-2482
Titre abrégé: BMC Surg
Pays: England
ID NLM: 100968567
Informations de publication
Date de publication:
27 Aug 2023
27 Aug 2023
Historique:
received:
30
01
2023
accepted:
23
07
2023
medline:
29
8
2023
pubmed:
28
8
2023
entrez:
27
8
2023
Statut:
epublish
Résumé
We compared the outcome of radical prostatectomy (RP) with seed brachytherapy (BT) in clinically localized prostate cancer (LPCa) using two different biochemical recurrence (BCR) definitions. Clinical data of 1117 patients with non-metastatic prostate cancer (PCa) treated with either RP or BT as the basis of the multimodal therapy from a single tertiary hospital between 2007 and 2021 were retrospectively analyzed. 843 LPCa patients (RP = 737, BT = 106) with at least one prostate-specific antigen (PSA) test after treatment were finally included. The BCR survival was evaluated by direct comparison and one-to-one propensity score matching (PSM) analysis using surgical definition (PSA ≥ 0.2ng/ml) for RP and surgical/Phoenix definition (PSA nadir + 2ng/ml ) for BT. The propensity score (PS) was calculated by multivariable logistic regression based on the clinicopathological parameters. Median follow-up was 43 months for RP patients and 45 months for BT patients. Kaplan-Meier analysis did not show any statistically significant differences in terms of BCR-free survival (BFS) between the two groups when using Phoenix definition for BT (P > 0.05). Similar results were obtained in all D'Amico risk groups when stratified analyses were conducted. However, RP achieved improved BFS compared to BT in the whole cohort and all risk groups with the surgical definition for BT(P < 0.05). After adjusting PS, 192 patients were divided into RP and BT groups (96 each). RP presented a better BFS than BT when using the surgical definition (P < 0.001), but no significant difference was found when using the Phoenix definition (P = 0.609). Inconsistent BCR-free survival outcomes were acquired using two different BCR definitions for BT patients. RP provided comparable BFS with BT using the Phoenix definition but better BFS using the surgical definition, regardless of whether the PSM was performed. Our findings indicated that an exact BCR definition was critical for prognostic assessment. The corresponding results will assist physicians in pretreatment consultation and treatment selection.
Identifiants
pubmed: 37635216
doi: 10.1186/s12893-023-02121-4
pii: 10.1186/s12893-023-02121-4
pmc: PMC10464079
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
253Subventions
Organisme : Natural Science Foundation of Beijing Municipality
ID : Z200027
Organisme : Cohort Construction Project of Peking University Third Hospital
ID : BYSYDL2021012
Organisme : Medicine-X Project of Peking University Health Science Center
ID : BMU2022MX014
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Transl Androl Urol. 2020 Apr;9(2):332-343
pubmed: 32420139
Brachytherapy. 2022 Nov-Dec;21(6):833-838
pubmed: 35902336
Eur Urol. 2016 Jul;70(1):21-30
pubmed: 26700655
Eur Urol Focus. 2020 Mar 15;6(2):404-418
pubmed: 31813810
J Clin Oncol. 2018 Apr 20;36(12):1192-1198
pubmed: 29489433
Chin Med J (Engl). 2021 Mar 17;134(7):783-791
pubmed: 33734139
J Urol. 2007 Feb;177(2):540-5
pubmed: 17222629
Lancet Oncol. 2012 Feb;13(2):189-95
pubmed: 22112793
BJU Int. 2012 Feb;109 Suppl 1:22-9
pubmed: 22239226
Ther Adv Urol. 2017 Oct 09;9(11):241-250
pubmed: 29662542
Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):962-975
pubmed: 28333019
Radiat Oncol. 2022 Apr 11;17(1):71
pubmed: 35410307
Cureus. 2021 Aug 23;13(8):e17400
pubmed: 34584809
Eur Urol. 2019 Jun;75(6):967-987
pubmed: 30342843
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
J Urol. 2019 Nov;202(5):973-978
pubmed: 31144590
Can Urol Assoc J. 2016 Aug;10(7-8):246-250
pubmed: 27878044
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74
pubmed: 16798415
Urology. 2020 Feb;136:180-189
pubmed: 31704459
N Engl J Med. 2016 Oct 13;375(15):1415-1424
pubmed: 27626136
Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1487-93
pubmed: 16750326
Radiat Oncol. 2014 May 06;9:107
pubmed: 24885896
World J Urol. 2020 Oct;38(10):2477-2484
pubmed: 31875247
Brachytherapy. 2018 Nov - Dec;17(6):837-844
pubmed: 30245169